ESC: J&J's Xarelto combo tops aspirin in artery disease, cueing $1.5B in U.S. sales
admin 28th August 2017 Uncategorised 0Johnson & Johnson and Bayer’s Xarelto has been feeling the heat in the next-gen anticoagulant market from high-flying rival Eliquis. Over the weekend, though, the medication got a big boost that could expand its potential treatment population by more than half.
More: ESC: J&J's Xarelto combo tops aspirin in artery disease, cueing .5B in U.S. sales
Source: fierce